The overwhelming federal nature of this subject is apparent,” the lawsuit alleges. “States are not free to tinker with ...

The pharma company said the drug combined with eltrombopag demonstrated a significant improvement in time to treatment ...

Novartis AG said an experimental medicine helped patients with an autoimmune disease in late-stage studies, offering a boost ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

A day after posting a pair of phase 3 wins for the tricky indication of Sjögren's syndrome, the Swiss pharma has unveiled a ...

Novartis has been evaluating a bid for Avidity, which had a market value of about $5.8bn at market close on Wednesday, and ...

The drug, ianalumab, met its objectives in two Phase 3 studies in Sjögren’s syndrome, boosting the outlook of a ...

Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the Financial Times ...

A mere 24 hours after Novartis' ianalumab hit the mark in two phase 3 trials in Sjogren's syndrome, the drug has delivered ...

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

Vas Narasimhan, chief executive officer of Novartis AG, in a 2018 photo. Narasimhan assumed the reigns as CEO a year ago, emphasizing the importance of digital and data for pharma R&D.

Novartis AG NOVN -0.38% launched a lottery-style program to provide doses of its pricey gene therapy free of charge, drawing criticism from patient groups that called it an inappropriate way to ...